Curated News
By: NewsRamp Editorial Staff
July 29, 2025
Scinai Immunotherapeutics' PC111 Shows Promise in Treating Dermatological Conditions
TLDR
- Scinai Immunotherapeutics' PC111 offers a competitive edge by providing a non-immunosuppressive treatment for pemphigus and SJS/TEN, potentially transforming care for these conditions and benefiting shareholders.
- PC111, a human anti-Fas Ligand monoclonal antibody, works by targeting soluble Fas Ligand to prevent blister formation in pemphigus, as confirmed in a peer-reviewed study.
- Scinai's PC111 could significantly improve lives by offering a new treatment option for pemphigus and SJS/TEN, conditions with high unmet medical needs.
- Discover how Scinai's PC111, a first-in-class antibody, is pioneering a novel approach to treat severe dermatological conditions without suppressing the immune system.
Impact - Why it Matters
This news is significant because it highlights a potential breakthrough in treating severe dermatological conditions like pemphigus and SJS/TEN with a non-immunosuppressive approach. The development of PC111 by Scinai Immunotherapeutics could offer new hope to patients suffering from these life-threatening conditions, marking a pivotal advancement in medical science and biopharmaceutical innovation.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company, has made a significant breakthrough with its first-in-class human anti-Fas Ligand monoclonal antibody, PC111. A peer-reviewed article in the Journal of Dermatological Treatment has confirmed PC111's disease-modifying potential, particularly in preventing blister formation in humanized models of pemphigus and its potential use in treating SJS/TEN, a life-threatening dermatological condition. This innovative approach offers a non-immunosuppressive solution to these high unmet-need indications, as highlighted by CEO Amir Reichman. The findings not only promise to transform treatment options for patients but also deliver meaningful value to shareholders. For more details, the full press release can be viewed here.
Scinai Immunotherapeutics Ltd. operates with two main business units: one focused on developing inflammation and immunology biological therapeutic products, and the other providing boutique CDMO services. Their innovative pipeline includes nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs. For further information, visit their website at www.Scinai.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics' PC111 Shows Promise in Treating Dermatological Conditions
